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Introduction
The concept of prosthesis-patient mismatch was introduced 
in 1978.[1] PPM occurs when the effective orifice area 
(EOA) of a prosthesis is too small for the patient’s body size, 
resulting in excessively high postoperative valve gradients.[2] 
Independent researchers evaluating valve performance in vivo 
by echocardiography have underlined the overestimation of EOA 
in tables[3,4] issued by valve manufacturers (based on in-vitro 
testing)[5,6] and this has resulted in revised valve specifications.[7]
Valve design has evolved from intra-annular implantation where 
the internal orifice diameter is smaller than the tissue annular 
diameter (TAD) to the introduction of supra-annular implantation 
where these diameters are equivalent.[8] This feature allows for 
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supra-annular implantation of a larger valve for a fixed TAD, often 
of the magnitude of one valve size. Various additional design 
features such as the TopHat design,[4] a lower-profile sewing 
ring and external mounting of pericardial tissue contribute to a 
larger EOA.[9]
The improvements in EOA are based on the premise that inferior 
haemodynamics result in suboptimal clinical outcomes. Studies 
have linked PPM with persistent left ventricular hypertrophy, 
diastolic dysfunction and curtailed functional improvement.[10] 
Late cardiac complications [11] and accelerated degeneration 
of bioprostheses have also been reported.[12] However, in the 
setting of advancing age, the combined effects of these factors 
on survival remains unclear.[13,14]
Although age undoubtedly increases early and late mortality after 
aortic valve replacement, the direct effect of mismatch remains 
debatable.[15-17] We studied the effect of the interaction of age 
and mismatch as well as the influence of iEOA on long-term 
survival both as a continuous variable, and as a categorical 
determinant of moderate or severe PPM.
Methods
586 consecutive patients (61.6% male, mean age 63.6±12.0) 
undergoing AVR ±CABG between January 1995 and December 
2016 in a single-surgeon’s practice were enrolled in the study 
and grouped according to age: 15-59 (n=148), 60-67 (n=145), 
68-74 (n=149), 74 or more (n=144). Patients were excluded if they 
underwent transcatheter valve implantation or other procedures. 
Baseline patient characteristics as well as postoperative 
complications were recorded in the presence or absence of 
PPM (table 1). Mortality data was obtained from the National 
Statistics database. Patients were followed up for a mean of 7.8 
years (median 7.3) up to a maximum of 20 years.  The Hospital 
Scientific Ethical Committee waived the necessity for consent as 
the study was retrospective and patient data was anonymized. 
The study protocol conformed to the ethical guidelines of the 
1975 Declaration of Helsinki.
Surgery was performed in a standard fashion under normothermic 
bypass with antegrade cold cardioplegia. We used the internal 
thoracic artery supplemented by saphenous vein grafts when 
additional coronary bypass was necessary. No patient included 
in this series underwent root enlargement. Ninety three percent of 
patients below 70 received a mechanical valve whereas 96% of 
patients over 70 received a bioprosthesis. The choice of valves 
implanted evolved with the introduction of models with a larger 
EOA, potentially providing superior haemodynamics (table 2). 
No PPM was defined as an indexed effective orifice area (iEOA) 
of >0.85cm2/m2, moderate PPM as 0.65-0.85cm2/m2 and severe 
as <0.65cm2/m2, and was calculated according to published 
data on valve EOA derived from independent researchers’ post-
operative echocardiographic studies (table 3).
Statistical Methods
The student’s t-test was used to compare age groups with or 
without PPM. The Cox proportional hazard model was used to 
study the impact of age, iEOA and PPM category on long-term 
survival. Survival analysis was performed using the facilities of 
the Statistical Package for Social Sciences (SPSS, Inc, Chicago, 
IL) by using both a non-parametric approach (Kaplan-Meier 
estimates) and semi-parametric approach (Cox regression 
analysis). The Log-Rank (Mantel-Cox) test was used to determine 
whether the Kaplan Meier survival curves for different age-groups 
differed significantly at the 0.05 level.
Results
Baseline characteristics and postoperative complications in 
patients without or with PPM did not differ, except for logistic/
EuroSCORE risk, which was affected by age (table 1). 
Table 1. Baseline patient characteristics and postoperative 
complications
parameter No PPM Yes PPM p value
n 419 167
age 65.87±11.69 63.35±10.61 0.016
female 155 (36.9%) 72 (42.9%) 0.180
urgent surgery 48 (11.4%) 21 (12.5%) 0.715
concomitant CABG 139 (33.1%) 59 (35.1%) 0.639
ejection fraction (%) 70.44±14.31 69.71±13.59 0.717
mean Parsonnet score 13.96±7.17 13.40±6.61 0.375
mean EuroScore 5.31±2.07 4.87±1.99 0.037
mean logistic EuroScore 5.02±3.94 4.26±3.00 0.046
mean hospital stay 
(survivors) 6.20±3.62 6.30±4.87 0.797
median ventilation time 
(hours) 8 7 0.387
patients transfused 118 (28.1%) 53 (31.5%) 0.405
mean transfusion volume 
(units) 1.26±2.41 1.11±2.20 0.576
mean haemorrhage 
volume (ml) 459.8±311.0 476.4±348.1 0.617
IABP usage 18 (4.3%) 4 (2.4%) 0.272
>24 hours inotropic 
support 116 (27.6%) 43 (25.6%) 0.618
atrial fibrillation/flutter 97 (23.1%) 47 (28.0%) 0.214
Table 2. Valves implanted during the study period
valve size 1995-2001* 2002-2015**
mechanical
19, 21 CarboMedics Reduced CarboMedics TopHat
23 CarboMedics Standard CarboMedics TopHat
25 CarboMedics Standard CarboMedics Standard
bioprosthetic
19, 21, 23
Carpentier Edwards 
Perimount Sorin Mitroflow
25 Carpentier Edwards Perimount
Carpentier Edwards 
Perimount/Magna
*11 St Jude Medical Toronto SPV valves inserted during this period
**7 Perceval valves inserted during this period
Original Article | 33International Cardiovascular Forum Journal 11 (2017)DOI: 10.17987/icfj.v11i0.432
412 of 586 patients were alive at the completion of the study. The 
survival curves display the Kaplan-Meier survival probabilities for 
each age group against survival duration (figure 1). The log-rank 
test show that the Kaplan Meier survival curves of the four age-
groups differ significantly when compared pairwise (table 4).
Survival was also plotted and analysed in relation to operative 
date, in five-year quartiles (figure 2). There was no influence on 
survival and the incidence of PPM within these quartiles was 
similar (p = 0.965) (table 5). 
140 patients received a size 25 valve, 202 patients received a 
size 23, 195 patients received a size 21, and 49 patients received 
a size 19 valve. The incidence of moderate PPM was 24.6% 
and severe PPM was 3.9% (figure 3). Mismatch was present 
in 167 patients and was more prevalent in younger patients. 
In fact, the mean age of patients with mismatch (63.35±10.61) 
was 2.52 years lower than their counterparts with no mismatch 
(65.87±11.69) and this difference is significant (p=0.016) 
(figure 4).
There was no correlation between PPM and perioperative 
mortality. There were 11 early deaths (1.9%), and of these, 
10 patients had no PPM and one had moderate PPM. Seven 
patients who died underwent concomitant coronary grafting 
and 8 were over 70 years old, both recognized risk factors for 
increased perioperative mortality. 
Survival probability was significantly affected by patient’s age 
with the hazard of dying increasing by around 7.3% for every 
incremental year. In patients with severe and moderate mismatch 
the hazards of dying were respectively 70.3% and 31.2% higher 
compared to patients with no PPM, but the increase was not 
statistically significant. In patients with mismatch the hazards of 
dying were 86.5% higher for 19mm valves, 68.7% for 21mm valves 
and 13.7% for 23mm valves compared to 25mm valves. These 
hazard ratios are not significant mainly because the incidence of 
mismatch was low, particularly for the larger valves. (table 6).
Table 3. EOA values
valve model size19EOA
size 21
EOA
size 23
EOA
size 25
EOA
reference 
source*
CarboMedics 1.0 1.54 1.63 1.98 [18,19]
Carpentier 
Edwards 1.1 1.5 1.8 1.8 [13,20,21]
Sorin Mitroflow 1.2 1.5 1.8 2.3 [13,22,23,24]
St Jude Medical 
Toronto SPV 1.3 1.5 1.7 [25]
*reference source refers to the publications quoting the EOA values 
used in this study 
Table 4. Log-Rank (Mantel-Cox) test relating survival time to 
age
age groups Chi-Square df p value
group 1 versus group 2 11.607 1 0.001
group 1 versus group 3 30.722 1 0.000
group 1 versus group 4 66.560 1 0.000
group 2 versus group 3 4.360 1 0.037
group 2 versus group 4 28.157 1 0.000
group 3 versus group 4 13.345 1 0.000
four groups collectively 80.057 3 0.000
df: degrees of freedom
Table 5. PPM incidence in five-year quartiles
period No PPM Yes PPM
1995-1999 89 37
70.6% 29.4%
2000-2004 117 49
70.5% 29.5%
2005-2009 93 36
72.1% 27.9%
2010-2015 120 45
72.7% 27.3%
total 419 167
71.5% 28.5%
X2(3) = 0.275, p = 0.965
Figure 1. Kaplan-Meier survival curves for the four age groups
Figure 2. Kaplan-Meier survival curves versus date of surgery 
(in five-year quartiles)
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Mean iEOA was 0.94±0.15cm2/m2. When iEOA was analysed as 
a continuous parameter rather than a categorical parameter, a 
higher iEOA was associated with a significantly reduced hazard 
ratio of dying. The chance of survival increased by 8.8% for every 
0.1 unit increment in iEOA (table 7). 
In conclusion, age was a significant predictor of long-term 
survival whereas prosthesis-patient mismatch failed to exert 
a statistically significant effect. This situation applied for both 
moderate and severe mismatch and for all valve sizes used. In 
contrast long-term survival was affected by iEOA when this was 
analyzed as a continuous variable.
Discussion
Cardiac-related mortality was shown to be increased by 
prosthesis-patient mismatch in a meta-analysis of 34 
observational studies published in 2012.[26] This analysis 
included a number of studies that failed to demonstrate a 
significant effect of PPM, amongst which were one study [27] 
with a longer mean follow-up (9.1 vs. 7.8 years) and a second 
[28] with a comparable follow-up (median of 7.3 vs. 7.3 years) to 
our study. Both these studies failed to show a significant effect 
on survival, raising the possibility that a longer follow-up may 
be salient. The authors stressed the value of preventing PPM, 
particularly in younger patients in whom long-term survival may 
be impacted to a greater extent. 
The incidence of common postoperative complications was 
similar in patients with or without PPM. Certain complications 
have been shown, by multivariate analysis, to affect long-term 
outcome. [29] In this study risk stratification was higher by logistic 
(p=0.046) and additive EuroSCORE (p=0.037) in patients without 
PPM because this group was older by 2.52 years, age being a 
contributor to the score. The incidence of mismatch is higher in 
younger patients and this may attenuate its effect on survival. 
Follow-up duration is inversely proportional to advancing age 
at operation. Studies with a longer follow-up have failed to 
demonstrate a deleterious effect of mismatch. The combined 
effect of a younger age and a longer follow-up may overshadow 
the importance of mismatch in determining long-term survival. 
Although mismatch leads to adverse cardiac events its effect on 
survival is reduced by advancing age.[29] Our results suggest 
that age, and its direct effect on follow-up duration, significantly 
affects survival whereas mismatch does not.
A long follow-up necessarily entails evolving practices including the 
implantation of novel valves that may significantly affect survival. 
Analysis of survival by operative date, in four five-year quartiles, 
showed no significant difference in survival in these groups.
When valve haemodynamics are translated into a continuum of 
iEOA a significant effect on long-term survival becomes evident. 
This relationship failed to reach statistical significance with 
mismatch because of the low incidence of moderate PPM, and 
the very low incidence of severe PPM. All data pertaining to valve 
EOA was obtained from published studies and not from our own 
post-operative measurements. These values should be readily 
available in theatre and act as a guide to the surgeon implanting 
an aortic prosthesis with the goal of avoiding mismatch.  Our 
study suggests that the largest size valve with the best possible 
EOA should always be implanted. In extreme circumstances of a 
small aortic root, enlargement may be performed. However, the 
increased operative risk of this procedure has not been shown to 
benefit long-term survival.[30]
Table 7. Cox regression relating survival time to age and iEOA: 
parameter 
estimate SE
Wald 
test df
p  
value
Hazard 
Ratio
95% 
lower
CI 
higher
age 0.0683 0.0082 69.38 1 0.000 1.071 1.054 1.088
iEOA -0.0921 0.0312 8.714 1 0.003 0.912 0.858 0.970
Wald test: used to test the true value of the parameter, based on 
the sample estimate df: degrees of freedom associated with each 
parameter estimate
Table 6. Cox regression relating survival time to age and PPM
parameter 
estimate SE
Wald 
test
p  
value
Hazard 
Ratio
95% 
lower
CI 
higher
age 0.0701 0.0092 58.06 0.000 1.073 1.053 1.092
severe  
PPM 0.5324 0.3251 2.682 0.101 1.703 0.901 3.221
moderate 
PPM 0.2715 0.2073 1.715 0.190 1.312 0.874 1.969
no PPM 0 1
size 19  
PPM 0.6234 0.3584 3.026 0.082 1.865 0.924 3.765
size 21  
PPM 0.5232 0.3143 2.771 0.096 1.687 0.911 3.124
size 23  
PPM 0.1287 0.2927 0.193 0.660 1.137 0.641 2.019
size 25  
PPM 0 1
SE: standard error, CI confidence interval
Figure 3. Distribution of PPM by severity: gray moderate, black 
severe
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Limitations
The data was derived from a single surgeon’s practice and may 
not be representative of a wider population. A change in the 
use of certain valve models during the study period may have 
influenced the outcome. The low incidence of mismatch may 
have been a factor limiting statistical significance.
Conclusion
PPM, whether moderate or severe, did not significantly curtail 
long-term survival. A larger iEOA increased survival by 8.8% per 
0.1 unit increase. Age exerted a significant effect on survival, 
reducing it by 7.3% for each incremental year. 
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